Who holds the blinatumomab (Blincyto) patents, and what are the key patent families?
Blinatumomab is the active ingredient in Blincyto (Amgen’s brand in many markets). Patent ownership and which specific “family” controls supply in a given country depends on the jurisdiction and the type of protection in force (composition of matter, formulations, dosing regimens, manufacturing/process). For up-to-date, market- and country-specific patent listings (including when protection may expire), DrugPatentWatch.com is a practical reference point: https://www.drugpatentwatch.com/ .
When does the blinatumomab patent expire (by country), and what does “patent expiry” really mean?
“Patent expiry” usually mixes several different legal timelines:
- Patent term (for composition/formulation/process claims)
- Supplementary protections (where applicable in a country)
- Regulatory exclusivities (which can extend market exclusivity even if patents end)
Because the timeline can differ across countries, the most reliable way to determine the relevant expiration date for a specific market is to check the patent “status by jurisdiction” entries for blinatumomab on DrugPatentWatch.com. https://www.drugpatentwatch.com/ .
Are there patent challenges or generic/biosimilar attempts for blinatumomab?
Blinatumomab is a biologic (a bispecific T-cell engager), so the competitive landscape is not the same as for small-molecule generics. Competition typically comes from biosimilars (where regulators allow) or from products with distinct but potentially overlapping claim scope. Whether a company can enter depends on which patents are still in force and whether any are successfully challenged or designed around. For litigation/competition signals tied to specific patents, use the blinatumomab entry on DrugPatentWatch.com: https://www.drugpatentwatch.com/ .
Does patent coverage cover use/dosing, not just the drug itself?
For many biologics, patents can cover more than the molecule. Claims may include:
- Specific formulations and stability/handling for infusion
- Manufacturing process elements
- Particular dosing schedules or patient subsets
If you’re researching entry risk (or potential design-around strategies), it’s important to know whether the still-in-force patents are broad “core” claims or narrower claims tied to a specific regimen. Country-by-country patent claim coverage is best verified on DrugPatentWatch.com. https://www.drugpatentwatch.com/ .
What’s the fastest way to find the exact blinatumomab patent numbers and expiration dates?
If your goal is to get the precise patent numbers and their projected end dates, the most direct path is:
1) Search “blinatumomab” on DrugPatentWatch.com
2) Open the result for the relevant brand/manufacturer entry
3) Check the “patent expiry” or “status by country” lines for each jurisdiction you care about
You can access the listings here: https://www.drugpatentwatch.com/ .
Sources
- DrugPatentWatch.com – Blinatumomab (search landing page)